Immunosuppression-induced bronchial epithelial-mesenchymal transition: a potential contributor to obliterative bronchiolitis.

[1]  R. Speich,et al.  Mycophenolate mofetil reduces alveolar inflammation, acute rejection and graft loss due to bronchiolitis obliterans syndrome after lung transplantation. , 2010, Pulmonary pharmacology & therapeutics.

[2]  Christopher M Waters,et al.  Epithelial repair mechanisms in the lung. , 2010, American journal of physiology. Lung cellular and molecular physiology.

[3]  S. Hodge,et al.  Posttransplant Bronchiolitis Obliterans Syndrome Is Associated with Bronchial Epithelial to Mesenchymal Transition , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  J. Lordan,et al.  Epithelial to mesenchymal transition (EMT) and airway remodelling after human lung transplantation , 2009, Thorax.

[5]  P. Marquet,et al.  Pharmacokinetic Optimization of Immunosuppressive Therapy in Thoracic Transplantation: Part II , 2009, Clinical pharmacokinetics.

[6]  P. Marquet,et al.  Pharmacokinetic Optimization of Immunosuppressive Therapy in Thoracic Transplantation: Part I , 2009, Clinical pharmacokinetics.

[7]  G. Gupte,et al.  Sirolimus-related pulmonary toxicity mimicking 'asthma like' symptoms. , 2007, World journal of gastroenterology.

[8]  B. Willis,et al.  TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[9]  Satohiro Masuda,et al.  An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. , 2006, Pharmacology & therapeutics.

[10]  A. Ramirez,et al.  Myofibroblast Transdifferentiation in Obliterative Bronchiolitis: TGF‐β Signaling Through Smad3‐Dependent and ‐Independent Pathways , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  B. Willis,et al.  Epithelial origin of myofibroblasts during fibrosis in the lung. , 2006, Proceedings of the American Thoracic Society.

[12]  J. Lordan,et al.  Phenotype of airway epithelial cells suggests epithelial to mesenchymal cell transition in clinically stable lung transplant recipients , 2005, Thorax.

[13]  T. McMorrow,et al.  Cyclosporine A-induced renal fibrosis: a role for epithelial-mesenchymal transition. , 2005, The American journal of pathology.

[14]  A. Nicholson,et al.  Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. , 2005, The American journal of pathology.

[15]  T. Mohanakumar,et al.  Airway Epithelium is the Primary Target of Allograft Rejection in Murine Obliterative Airway Disease , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  B. Milleron,et al.  Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF‐β and IL-10 , 2003, European Respiratory Journal.

[17]  J. Greenberger,et al.  Bone marrow origin of myofibroblasts in irradiation pulmonary fibrosis. , 2003, American journal of respiratory cell and molecular biology.

[18]  K. O'Reilly,et al.  Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. , 2001, Clinical immunology.

[19]  David W. Johnson,et al.  Fibrogenic Effects of Cyclosporin A on the Tubulointerstitium: Role of Cytokines and Growth Factors , 1999, Nephron Experimental Nephrology.

[20]  P. Hasleton,et al.  Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation. , 1999, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[21]  R. Speich,et al.  Bronchiolitis obliterans after lung transplantation: a review. , 1998, Chest.

[22]  J. Kirby,et al.  Differential effects of cyclosporin A and tacrolimus on the production of TGF-β: implications for the development of obliterative bronchiolitis after lung transplantation , 1998, Transplant international : official journal of the European Society for Organ Transplantation.

[23]  W. Schürch,et al.  The myofibroblast: a quarter century after its discovery. , 1998, The American journal of surgical pathology.

[24]  P. Halloran,et al.  The "injury response": a concept linking nonspecific injury, acute rejection, and long-term transplant outcomes. , 1997, Transplantation proceedings.

[25]  B. Griffith,et al.  Clinical trial of tacrolimus versus cyclosporine in lung transplantation. , 1995, The Annals of thoracic surgery.

[26]  S. Tullius,et al.  Both alloantigen-dependent and -independent factors influence chronic allograft rejection. , 1995, Transplantation.

[27]  D. Phillips,et al.  A novel epithelial cell from neonatal rat lung: isolation and differentiated phenotype. , 1990, The American journal of physiology.

[28]  G. Berry,et al.  A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Lung Rejection Study Group. The International Society for Heart Transplantation. , 1990, The Journal of heart transplantation.

[29]  M. Hammond,et al.  A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. , 1990, The Journal of heart transplantation.

[30]  B. Myers,et al.  Cyclosporine-associated chronic nephropathy. , 1984, The New England journal of medicine.

[31]  J. Losman.  The International Society for Heart Transplantation , 1982 .